SCHEMBL5003471

SCHEMBL5003471

Cc1ccc(-c2cncc(N3CCN(c4ccccn4)CC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
HSD17B10 Q99714 6/20 0.54
LMNA P02545 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
HTT P42858 3/20 0.54
POLB P06746 3/20 0.54
MAPK1 P28482 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
ACHE P22303 1/20 0.54
BACE1 P56817 1/20 0.54
KDM4E B2RXH2 13/20 0.52
TSHR P16473 3/20 0.52
TP53 P04637 2/20 0.52
HPGD P15428 2/20 0.52
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 8/20 0.50
GAA P10253 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5000896 0.87 DRD2 (0.58) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL4997684 0.87 BCHE (0.54) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL5003442 0.86 MAPT (0.47) MAPTLMNAACHEKDM4EALDH1A1
SCHEMBL4997810 0.86 MAPT (0.49) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL5003434 0.86 ACHE (0.57) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL4997188 0.84 HRH3 (0.53) MAPTLMNAHTTPOLBMAPK1
SCHEMBL4996260 0.84 CHEK1 (0.48) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL4997696 0.84 CHEK1 (0.53) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL5000610 0.84 SORD (0.51) MAPTHSD17B10LMNASMN1; SMN2HTT
SCHEMBL4995301 0.84 MAPK1 (0.51) MAPTHSD17B10LMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C MAPT 5/4885HSD17B10 1811/4885LMNA 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.